Antioxidants (Oct 2020)

Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects

  • Marina Galicia-Moreno,
  • Silvia Lucano-Landeros,
  • Hugo Christian Monroy-Ramirez,
  • Jorge Silva-Gomez,
  • Jorge Gutierrez-Cuevas,
  • Arturo Santos,
  • Juan Armendariz-Borunda

DOI
https://doi.org/10.3390/antiox9100980
Journal volume & issue
Vol. 9, no. 10
p. 980

Abstract

Read online

Liver diseases represent a critical health problem with 2 million deaths worldwide per year, mainly due to cirrhosis and its complications. Oxidative stress plays an important role in the development of liver diseases. In order to maintain an adequate homeostasis, there must be a balance between free radicals and antioxidant mediators. Nuclear factor erythroid 2-related factor (Nrf2) and its negative regulator Kelch-like ECH-associated protein 1 (Keap1) comprise a defense mechanism against oxidative stress damage, and growing evidence considers this signaling pathway as a key pharmacological target for the treatment of liver diseases. In this review, we provide detailed and updated evidence regarding Nrf2 and its involvement in the development of the main liver diseases such as alcoholic liver damage, viral hepatitis, steatosis, steatohepatitis, cholestatic damage, and liver cancer. The molecular and cellular mechanisms of Nrf2 cellular signaling are elaborated, along with key and relevant antioxidant drugs, and mechanisms on how Keap1/Nrf2 modulation can positively affect the therapeutic response are described. Finally, exciting recent findings about epigenetic modifications and their link with regulation of Keap1/Nrf2 signaling are outlined.

Keywords